Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders

Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.
In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.
Highlights from the episode:
Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).
How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).
The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).
Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).
Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).
The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).
Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).
Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).
Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.
In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.
Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.
Connect with Anthony Catacchio:
LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b
Product Insight website: www.productinsight.com
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show

How solid is your CMC foundation—and what happens if it cracks under pressure?
David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.
His “house building” approach demystifies CMC’s complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.
Tune in to hear Henri’s practical wisdom distilled through real-world analogies:
Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)
Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)
Process validation explained: FDA’s three stages, from control strategy justification to continued verification (05:15)
Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)
Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)
Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)
Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)
The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)
Smart insight:
Never underestimate CMC. If you do, you will pay for it later.
If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:
Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
Connect with Henri Kornmann:
LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show

Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.
Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.
In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.
What you will learn:
Evolution of cell bank technology and regulatory expectations (00:33)
The impact of weak CMC foundations on late-stage failure (00:51)
Lessons learned from Ferring’s gene therapy approval and CMC gap analysis (06:51)
FDA statistics on CMC issues in INDs and response letters (08:07)
Critical early decisions: cell bank clonality and proper storage practices (10:22)
The importance of comprehensive raw material documentation (12:29)
Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)
Supply strategy for phase 2—why stability and batch knowledge matter (14:49)
Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)
Common pitfalls in CQA identification and continued process verification (17:01)
Smart insight:
The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.
In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.
If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:
Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
Connect with Henri Kornmann:
LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show

What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.
In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.
Topics covered:
The strategic advantage of B2B commercialization in consumer care biotech (02:46)
Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)
Building a pilot facility and moving toward technology licensing for global reach (05:33)
Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)
Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)
What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)
Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)
Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)
The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)
Strategic insight:
Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.
Explore the full story and hear Tim’s advice for both founders and innovators.
If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:
Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
Connect with Tim Corcoran:
LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/
Deep Blue Biotech: www.deepbluebiotech.com
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show

The chemicals industry remains locked into carbon-intensive, fossil-based manufacturing. Even engineered microbes like yeast or E. coli depend on expensive sugar feedstocks while generating significant waste. What if a photosynthetic organism could eliminate those constraints entirely—while commanding premium pricing as "ocean-derived"?
On the Smart Biotech Scientist Podcast, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, reveals how a recently discovered fast-growing marine cyanobacteria strain is unlocking carbon-neutral chemical production at costs below conventional fermentation. With his background spanning economics, operations, and innovation commercialization, Tim challenges conventional assumptions about synthetic biology scale-up, market entry strategy, and what actually separates successful biotechs from valley-of-death casualties.
Key topics discussed:
Tim Corcoran’s background in commercial roles, his pivot to biotech, and the founding story of Deep Blue Biotech (03:41)
Overview of cyanobacteria biology: photosynthetic efficiency and its legacy in Earth's atmosphere (07:22)
What makes the discovered ocean-based strain unique—and its advantages in robustness, growth rate, and use in personal care (08:27)
Commercial challenges and scientific limitations that have made cyanobacteria difficult to industrialize—plus recent breakthroughs (9:38)
Comparison with legacy hosts such as E. coli, yeast, microalgae: efficiency, feedstocks, genetic tractability, and downstream processing
(11:02)
The significance of direct secretion for lowering production costs and reducing CO₂ footprint (14:38)
Scale-up strategies with photobioreactors: modularity, light and CO₂ management, and future tech improvements (15:17)
Commercial strategy: starting with high-value personal care hyaluronic acid, regulatory considerations, and the rationale for this approach (17:17)
The importance of aligning scientific innovation with market needs and early customer discovery (20:31)
Long-term vision: potential for cyanobacteria in sustainable production of commodity chemicals like biofuels and the impact on global emissions (22:04)
Strategic insight:
Deep Blue Biotech's "premium-first commercialization" mirrors Tesla's playbook: start with high-margin applications ($2,000/kg hyaluronic acid for personal care) to generate immediate revenue and prove the platform. These early profits fund continuous strain engineering and process optimization, progressively driving down cost-of-goods while improving volumetric productivity. Only after establishing economic viability at premium pricing does the company target large-volume commodity markets—sustainable fuels, industrial chemicals—where success requires demonstration of competitive economics at industrial scale.
Discover how this photosynthetic organisms could decarbonize entire chemical supply chains while improving manufacturing economics. Part 2 reveals the strategic decisions separating synthetic biology winners from failures, photobioreactor infrastructure challenges, and why licensing beats building multiple facilities.
If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:
Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
Conn
One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.
Support the show